High Tide's German Subsidiary Reports Record 7.6 Tonnes Medical Cannabis Distribution, Accelerating Market Leadership

summarizeSummary

High Tide Inc.'s 51%-owned German subsidiary, Remexian Pharma GmbH, achieved a record 7.6 tonnes in medical cannabis distribution for Q2 2026, marking significant sequential and year-over-year growth in the German market.

check_boxKey Events

• Record Medical Cannabis Distribution

  Remexian Pharma GmbH, High Tide's 51%-owned German subsidiary, distributed a record 7.6 tonnes of medical cannabis in the second fiscal quarter ended April 30, 2026.

• Significant Volume Growth

  This record volume represents a 21% increase on a sequential basis and a 49% increase year-over-year, demonstrating strong operational momentum.

• Accelerating German Market Leadership

  The company states this performance is clear evidence of its model scaling in Europe's largest medical cannabis market, with Remexian holding over 10% of Germany's imported tonnage.

• Strategic European Expansion

  CEO Raj Grover highlighted the repeatable, capital-efficient distribution engine being built, with intentions to leverage this momentum for further expansion across Europe.

auto_awesomeAnalysis

This filing highlights strong operational execution and market penetration for High Tide in the crucial German medical cannabis market. The record distribution volume, with substantial sequential and year-over-year growth, demonstrates the effectiveness of their strategy to leverage Canadian procurement capabilities for European expansion. This positive operational news, coming shortly after securing significant credit facilities on May 5, 2026, reinforces the company's financial stability and growth trajectory, suggesting a robust outlook for its international segment.